Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF

Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF

IntroductionShrimp is a common but understudied food allergen with relatively high rates of emergency department visits. Here we report the shrimp OIT outcomes in the MOTIF (NCT03504774) clinical trial and discuss some of the challenges with performing this study.MethodsIn this phase 2 clinical tria...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Shirley Y. Jiang, Shu Cao, Kristine Martinez, Reyna Sharma, Olivia Raeber, Andrea Fernandes, Dinara Bogetic, Abhinav Kaushik, Sheena Gupta, Monali Manohar, Holden T. Maeker, Andrew R. Chin, Andrew J. Long, Catherine Feight, Margaret Woch, Kari C. Nadeau, R. Sharon Chinthrajah, Sayantani B. Sindher
Формат: Статья
Язык:английский
Опубликовано: Frontiers Media S.A. 2025-07-01
Серии:Frontiers in Allergy
Предметы:
shrimp
allergy
oral immunotherapy
clinical trial
double-blind placebo-controlled food challenge
Online-ссылка:https://www.frontiersin.org/articles/10.3389/falgy.2025.1458131/full
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!
Логин Для информации по задолженностям и напоминаниям

Internet

https://www.frontiersin.org/articles/10.3389/falgy.2025.1458131/full

Схожие документы